Skip to main content

Fight against pandemics

Women and children’s health

Funding and quality of aid

Research and Development

Opinions

EU Pharma Strategy
Blog series

Transparency is key to unlocking better policies

By Ellen T'Hoen, lawyer and director of Medicine Law & Policy

Social network

To stay in touch with Global Health Advocates,
follow us on Twitter

Phew! That was close.

Harmful and only #BigPharma friendly amendments by @WeissPernille rejected by majority of MEPs.

❌364✅263 - am 1

❌350✅279 - am 2

Good to see MEPs once again standing for transparent R&D, affordable 💊 and responsible incentives in the EU.

Consumers, just like CSOs, want more transparency on drug R&D costs, higher returns on public investment & find it unfair that some medicines aren't developed due to commercial reasons #EUPharma #AccessToMedicines

More info on @beuc's report ➡️ https://www.beuc.eu/sites/default/files/publications/BEUC-X-2022-117_What_consumers_think_of_medicine_prices_today_Report.pdf

At the round table today discussing #nutrition as a health determinant & the interlinkages between nutrition & health both in development & humanitarian settings — with great experts from @OxfamEU @GHABrussels @PlanEU @Concern @WorldVisionEU & @EU_Commission

#ChildHealthWeek